Skip to content Skip to footer

Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology 

  Shots: Teva and mAbxience have entered into a second global licensing agreement to develop an anti PD-1 biosimilar candidate in oncology As per the agreement, mAbxience will employ its state-of-the-art, cGMP-compliant facilities in Spain and Argentina for the development & production of biosimilar while Teva will handle its regulatory approvals & commercialization The agreement…

Read more